Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03428217
Title CB-839 With Cabozantinib vs. Placebo With Cabozantinib in Patients With Metastatic Renal Cell Carcinoma (CANTATA)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Calithera Biosciences, Inc
Indications

renal cell carcinoma

Therapies

Cabozantinib

Cabozantinib + Telaglenastat

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU


No variant requirements are available.